New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab

References

• HayatMJHowladerNReichmanMEEdwardsBKCancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) ProgramOncologist2007121203717227898
   PubMed Web of Science ®Google Scholar
• HolickCNGiovannucciELRosnerBStampferMJMichaudDSProspective study of cigarette smoking and adult glioma: dosage, duration, and latencyNeuro Oncol20079332633417504930
   PubMed Web of Science ®Google Scholar
• HuncharekMKupelnickBWheelerLDietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studiesJ Environ Pathol Toxicol Oncol200322212913714533876
   PubMedGoogle Scholar
• KaripidisKKBenkeGSimMROccupational exposure to ionizing and non-ionizing radiation and risk of non-Hodgkin lymphomaInt Arch Occup Environ Health200780866367017334774
   PubMed Web of Science ®Google Scholar
• KaripidisKKBenkeGSimMRYostMGilesGOccupational exposure to low frequency magnetic fields and the risk of low grade and high grade gliomaCancer Causes Control200718330531317260179
   PubMed Web of Science ®Google Scholar
• InskipPDTaroneREHatchEECellular-telephone use and brain tumorsN Engl J Med20013442798611150357
   PubMed Web of Science ®Google Scholar
• VilchezRAButelJSEmergent human pathogen simian virus 40 and its role in cancerClin Microbiol Rev200417349550815258090
   PubMed Web of Science ®Google Scholar
• ReussDvon DeimlingAHereditary tumor syndromes and gliomasRecent Results Cancer Res20091718310219322539
   PubMedGoogle Scholar
• KrexDKlinkBHartmannCLong-term survival with glioblastoma multiformeBrain2007130Pt 102596260617785346
   PubMed Web of Science ®Google Scholar
• SmithJSJenkinsRBGenetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implicationsFront Biosci20005D213D23110702383
   PubMed Web of Science ®Google Scholar
• LacroixMAbi-SaidDFourneyDRA multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJ Neurosurg200195219019811780887
   PubMed Web of Science ®Google Scholar
• HessKRExtent of resection as a prognostic variable in the treatment of gliomasJ Neurooncol199942322723110433106
   PubMed Web of Science ®Google Scholar
• MetcalfeSEGrantRBiopsy versus resection for malignant gliomaCochrane Database Syst Rev20013CD00203411687008
   PubMedGoogle Scholar
• BloomHJCombined modality therapy for intracranial tumorsCancer1975351111120162849
   PubMed Web of Science ®Google Scholar
• SalazarOMRubinPFeldsteinMLPizzutielloRHigh dose radiation therapy in the treatment of malignant gliomas: final reportInt J Radiat Oncol Biol Phys197951017331740231023
   PubMed Web of Science ®Google Scholar
• WalkerMDAlexanderEJrHuntWEEvaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trialJ Neurosurg1978493333343355604
   PubMed Web of Science ®Google Scholar
• WalkerMDGreenSBByarDPRandomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgeryN Engl J Med198030323132313297001230
   PubMed Web of Science ®Google Scholar
• WalkerMDStrikeTAShelineGEAn analysis of dose-effect relationship in the radiotherapy of malignant gliomasInt J Radiat Oncol Biol Phys197951017251731231022
   PubMed Web of Science ®Google Scholar
• FineHADearKBLoefflerJSBlackPMCanellosGPMeta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adultsCancer1993718258525978453582
   PubMed Web of Science ®Google Scholar
• CairncrossJGMacdonaldDRSuccessful chemotherapy for recurrent malignant oligodendrogliomaAnn Neurol19882343603643382171
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• WongETHessKRGleasonMJOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol19991782572257810561324
   PubMed Web of Science ®Google Scholar
• WHLThe vascular pattern of tumorsJohns Hopkins Hosp Bull192741156162
   Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• FolkmanJAnti-angiogenesis: new concept for therapy of solid tumorsAnn Surg197217534094165077799
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
   PubMed Web of Science ®Google Scholar
• SholleyMMFergusonGPSeibelHRMontourJLWilsonJDMechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cellsLab Invest19845166246346209468
   PubMed Web of Science ®Google Scholar
• FolkmanJAngiogenesis in psoriasis: therapeutic implicationsJ Invest Dermatol197259140435039962
   PubMed Web of Science ®Google Scholar
• MillerJWAdamisAPShimaDTVascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate modelAm J Pathol199414535745847521577
   PubMed Web of Science ®Google Scholar
• MoultonKSAngiogenesis in atherosclerosis: gathering evidence beyond speculationCurr Opin Lipidol200617554855516960504
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF and the quest for tumour angiogenesis factorsNat Rev Cancer200221079580312360282
   PubMed Web of Science ®Google Scholar
• BalukPHashizumeHMcDonaldDMCellular abnormalities of blood vessels as targets in cancerCurr Opin Genet Dev200515110211115661540
   PubMed Web of Science ®Google Scholar
• HanahanDFolkmanJPatterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell19968633533648756718
   PubMed Web of Science ®Google Scholar
• FolkmanJAngiogenesis: an organizing principle for drug discovery?Nat Rev Drug Discov20076427328617396134
   PubMed Web of Science ®Google Scholar
• FolkmanJIs angiogenesis an organizing principle in biology and medicine?J Pediatr Surg200742111117208533
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
   PubMed Web of Science ®Google Scholar
• FangJShingYWiederschainDMatrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor modelProc Natl Acad Sci U S A20009783884388910760260
   PubMed Web of Science ®Google Scholar
• MaxwellPHDachsGUGleadleJMHypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growthProc Natl Acad Sci U S A19979415810481099223322
   PubMed Web of Science ®Google Scholar
• ShweikiDItinASofferDKeshetEVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature199235963988438451279431
   PubMed Web of Science ®Google Scholar
• PlateKHBreierGWeichHARisauWVascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature199235963988458481279432
   PubMed Web of Science ®Google Scholar
• AugustePGurselDBLemiereSInhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanismsCancer Res20016141717172611245488
   PubMed Web of Science ®Google Scholar
• SalmaggiAEoliMFrigerioSIntracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant gliomaJ Neurooncol200362329730312777082
   PubMed Web of Science ®Google Scholar
• SchmidtNOWestphalMHagelCLevels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesisInt J Cancer199984110189988225
   PubMed Web of Science ®Google Scholar
• LiMRansohoffRMThe roles of chemokine CXCL12 in embryonic and brain tumor angiogenesisSemin Cancer Biol200919211111519038344
   PubMed Web of Science ®Google Scholar
• HallbookFWilsonKThorndykeMOlinskiRPFormation and evolution of the chordate neurotrophin and Trk receptor genesBrain Behav Evol200668313314416912467
   PubMed Web of Science ®Google Scholar
• HuangEJReichardtLFTrk receptors: roles in neuronal signal transductionAnnu Rev Biochem20037260964212676795
   PubMed Web of Science ®Google Scholar
• NicoBMangieriDBenagianoVCrivellatoERibattiDNerve growth factor as an angiogenic factorMicrovasc Res200875213514117764704
   PubMed Web of Science ®Google Scholar
• KraemerRHempsteadBLNeurotrophins: novel mediators of angiogenesisFront Biosci20038s1181118612957860
   PubMed Web of Science ®Google Scholar
• HoodJDChereshDARole of integrins in cell invasion and migrationNat Rev Cancer2002229110012635172
   PubMed Web of Science ®Google Scholar
• SunLHuiAMSuQNeuronal and glioma-derived stem cell factor induces angiogenesis within the brainCancer Cell20069428730016616334
   PubMed Web of Science ®Google Scholar
• SengerDRGalliSJDvorakAMPerruzziCAHarveyVSDvorakHFTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience198321945879839856823562
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun198916128518582735925
   PubMed Web of Science ®Google Scholar
• ConnollyDTOlanderJVHeuvelmanDHuman vascular permeability factor. Isolation from U937 cellsJ Biol Chem19892643320017200242584205
   PubMed Web of Science ®Google Scholar
• HouckKAFerraraNWinerJCachianesGLiBLeungDWThe vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNAMol Endocrinol1991512180618141791831
   PubMed Web of Science ®Google Scholar
• LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
   PubMed Web of Science ®Google Scholar
• de VriesCEscobedoJAUenoHHouckKFerraraNWilliamsLTThe fms-like tyrosine kinase, a receptor for vascular endothelial growth factorScience199225550479899911312256
   PubMed Web of Science ®Google Scholar
• ShibuyaMYamaguchiSYamaneANucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms familyOncogene1990545195242158038
   PubMed Web of Science ®Google Scholar
• OlssonAKDimbergAKreugerJClaesson-WelshLVEGF receptor signalling – in control of vascular functionNat Rev Mol Cell Biol20067535937116633338
   PubMed Web of Science ®Google Scholar
• TermanBIDougher-VermazenMCarrionMEIdentification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochem Biophys Res Commun19921873157915861417831
   PubMed Web of Science ®Google Scholar
• TakahashiMMatsuiAInaoMMochidaSFujiwaraKERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cellsHepatol Res200326323223612850696
   PubMed Web of Science ®Google Scholar
• TakahashiTShibuyaMThe 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblastsOncogene19971417207920899160888
   PubMed Web of Science ®Google Scholar
• JonesMKItaniRMWangHActivation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injuryAm J Physiol19992766 Pt 1G1345G135510362637
   PubMedGoogle Scholar
• GerberHPMcMurtreyAKowalskiJVascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activationJ Biol Chem19982734630336303439804796
   PubMed Web of Science ®Google Scholar
• GilleHKowalskiJLiBAnalysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutantsJ Biol Chem200127653222323011058584
   PubMed Web of Science ®Google Scholar
• HellstromMPhngLKHofmannJJDll4 signalling through Notch1 regulates formation of tip cells during angiogenesisNature2007445712977678017259973
   PubMed Web of Science ®Google Scholar
• RidgwayJZhangGWuYInhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesisNature200644471221083108717183323
   PubMed Web of Science ®Google Scholar
• Noguera-TroiseIDalyCPapadopoulosNJBlockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesisNature200644471221032103717183313
   PubMed Web of Science ®Google Scholar
• BoultonMECaiJGrantMBgamma-Secretase: a multifaceted regulator of angiogenesisJ Cell Mol Med200812378179518266961
   PubMed Web of Science ®Google Scholar
• SelkoeDKopanRNotch and Presenilin: regulated intramembrane proteolysis links development and degenerationAnnu Rev Neurosci20032656559712730322
   PubMed Web of Science ®Google Scholar
• BoultonMECaiJGrantMBZhangYGamma-secretase regulates VEGFR-1 signalling in vascular endothelium and RPEAdv Exp Med Biol200861331331918188959
   PubMed Web of Science ®Google Scholar
• HiranoHLopesMBLawsERJrInsulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomasNeuro Oncol19991210911911550306
   PubMedGoogle Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• MatsumotoTClaesson-WelshLVEGF receptor signal transductionSci STKE20012001112RE2111741095
   PubMedGoogle Scholar
• BenjaminLEGolijaninDItinAPodeDKeshetESelective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJ Clin Invest199910321591659916127
   PubMed Web of Science ®Google Scholar
• KuDDZaleskiJKLiuSBrockTAVascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteriesAm J Physiol19932652 Pt 2H586H5928368362
   PubMed Web of Science ®Google Scholar
• ClaussMGerlachMGerlachHVascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migrationJ Exp Med19901726153515452258694
   PubMed Web of Science ®Google Scholar
• GabrilovichDIChenHLGirgisKRProduction of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNat Med1996210109611038837607
   PubMed Web of Science ®Google Scholar
• CarmelietPBlood vessels and nerves: common signals, pathways and diseasesNat Rev Genet20034971072012951572
   PubMed Web of Science ®Google Scholar
• CalabreseCPoppletonHKocakMA perivascular niche for brain tumor stem cellsCancer Cell2007111698217222791
   PubMed Web of Science ®Google Scholar
• RubensteinJLKimJOzawaTAnti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooptionNeoplasia20002430631411005565
   PubMed Web of Science ®Google Scholar
• KunkelPUlbrichtUBohlenPInhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2Cancer Res200161186624662811559524
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res19975720459345999377574
   PubMed Web of Science ®Google Scholar
• LinYSNguyenCMendozaJLPreclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorJ Pharmacol Exp Ther199928813713789862791
   PubMed Web of Science ®Google Scholar
• IgnoffoRJOverview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factorAm J Health Syst Pharm20046121 Suppl 5S21S2615552623
   PubMed Web of Science ®Google Scholar
• CabebeEWakeleeHRole of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitorsCurr Treat Options Oncol200781152717634832
   PubMedGoogle Scholar
• EscudierBCosaertJPisaPBevacizumab: direct anti-VEGF therapy in renal cell carcinomaExpert Rev Anticancer Ther20088101545155718925847
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHambletonJMassRDHurwitzHIBergslandESarkarSCombined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol200523163706371215867200
   PubMed Web of Science ®Google Scholar
• MillerKDE2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancerClin Breast Cancer20033642142212636887
   PubMedGoogle Scholar
• AliSAMcHaylehWMAhmadABevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 casesJ Neurosurg2008109226827218671639
   PubMed Web of Science ®Google Scholar
• NarayanaAKellyPGolfinosJAntiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalJ Neurosurg2009110117318018834263
   PubMed Web of Science ®Google Scholar
• PoulsenHSGrunnetKSorensenMBevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursActa Oncol2009481525819031176
   PubMed Web of Science ®Google Scholar
• ZunigaRMTorcuatorRJainREfficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol200991332933618953493
   PubMed Web of Science ®Google Scholar
• KangTYJinTElinzanoHPeereboomDIrinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safetyJ Neurooncol200889111311818438609
   PubMed Web of Science ®Google Scholar
• NghiemphuPLLiuWLeeYBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology200972141217122219349600
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology200834701077978718316689
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
   PubMed Web of Science ®Google Scholar
• BallmanKVBucknerJCBrownPDThe relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro Oncol200791293817108063
   PubMed Web of Science ®Google Scholar
• LambornKRYungWKChangSMProgression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasNeuro Oncol2008410216217018356283
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• BatchelorTTGilbertMRSupkoJGPhase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11Neuro Oncol200461212714769136
   PubMed Web of Science ®Google Scholar
• PradosMDLambornKYungWKA phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyNeuro Oncol20068218919316533878
   PubMed Web of Science ®Google Scholar
• MohileNAALLymberisSCKarimiSHouBLGutinPHA pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomasASCO Meeting Abstracts20072518 Suppl2028
   Google Scholar
• NicholasMKLRArzbaecherJPaleologosNKrouwerHMalkinMBevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II studyASCO Meeting Abstracts20092715S2016
   Google Scholar
• LaiAFilkaEMcGibbonBPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
   PubMed Web of Science ®Google Scholar
• NarayanaAGolfinosJGFischerIFeasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade gliomaInt J Radiat Oncol Biol Phys200872238338918793954
   PubMed Web of Science ®Google Scholar
• GruberMLRazaSBevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicityASCO Meeting Abstracts20092715S2017
   Google Scholar
• GilbertMarc R RTOG. Temozolomide and Radiation Therapy with or without Bevacizumab in treating patients with newly diagnosed glioblstoma or Gliosarcoma. http://clinicaltrials.gov/ct2/show/NCT00884741
   Google Scholar
• Hoffmann-LaRocheCTA study of Avastin in combination with Temozolomide and Radiotherapy in patients with newly diagnsoed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00943826
   Google Scholar
• AnanthnarayanSBahngJRoringJTime course of imaging changes of GBM during extended bevacizumab treatmentJ Neurooncol2008788333934718389177
   PubMed Web of Science ®Google Scholar
• WefelJSCTZazzaliJFriedmanHSfor the BINeurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN studyASCO Meeting Abstracts20092715S20256
   Google Scholar
• PopeWBKimHJHuoJRecurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentRadiology2009252118218919561256
   PubMed Web of Science ®Google Scholar
• DesjardinsABDHerndonJEIIReardonDAQuinnJARichJNDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11)ASCO Meeting Abstracts20072518 Suppl2029
   Google Scholar
• PaldinoMDAFriedmanHSVredenburghJJBarboriakDPPrognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumabASCO Meeting Abstracts20092715S2058
   Google Scholar
• Lucio-EterovicAKPiaoYde GrootJFMediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyClin Cancer Res200915144589459919567589
   PubMed Web of Science ®Google Scholar
• IwamotoFMAbreyLEBealKPatterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology200973151200120619822869
   PubMed Web of Science ®Google Scholar
• QuantECNordenADDrappatzJRole of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumabNeuro Oncol200911555055519332770
   PubMed Web of Science ®Google Scholar
• PotthastLCSPanEYuDZhuWBremSThe infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumabASCO Meeting Abstracts20092715S2057
   Google Scholar